Microgen Development Will Allow To Treat Cerebral Palsy
The Scientific and Production Association Microgen of the Naсimbio holding (Rostec State Corporation) completed research on the expansion of indications for Relatox in the treatment of spastic forms of cerebral palsy in children aged 7 to 12 years.
The research results confirm the efficacy and safety of the Russian botulinum toxin type A for the treatment of muscle spasticity in both upper and lower extremities. Earlier, the company successfully completed the first in Russia similar clinical studies of the drug use in children aged 13–17 years, which allowed Relatox to become the first completely domestic medicine indicated for the treatment of this disease.
Relatox is the first and only domestic botulinum toxin type A, manufactured on the principle of the full cycle in Russia. SPA Microgen began its development in 2001. The drug is applied both in aesthetic medicine to correct cosmetic skin defects, eliminate wrinkles, treat blepharospasm, and in neurology — in patients with the upper extremity spasticity and the history of stroke. In March 2017, the company confirmed the approval of the drug and received marketing authorization with the inclusion of Relatox in the State Register of Pharmaceutical Products for Medical Purposes on an unlimited basis.
Today, SPA Microgen has also completed clinical studies of Relatox for hyperhidrosis (increased sweating) treatment.
Every year the increase in the number of people with cerebral palsy is about 2 %. In Moscow, there are about 10,000 people with disabilities with cerebral palsy, half of whom are children. In the Moscow region — about 5,000 people. Based on the frequency of birth of children with signs of cerebral palsy (5.0–6.0 per 1,000 people), some experts in Russia amount about a million people with this disease.